Merus N.V. Revenue and Competitors
Estimated Revenue & Valuation
- Merus N.V.'s estimated annual revenue is currently $45.3M per year.
- Merus N.V.'s estimated revenue per employee is $155,000
Employee Data
- Merus N.V. has 292 Employees.
- Merus N.V. grew their employee count by 6% last year.
Merus N.V.'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Director Portfolio Strategy & Chief Staff | Reveal Email/Phone |
2 | Chief Accounting Officer (CAO) | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | Head Precision Medicine, Strategy & Commercialization | Reveal Email/Phone |
6 | VP, Clinical and Bioanalytical Sciences | Reveal Email/Phone |
7 | VP Financial Planning Analysis | Reveal Email/Phone |
8 | VP Program and Alliance Management | Reveal Email/Phone |
9 | VP Clinical Development | Reveal Email/Phone |
10 | VP Product Strategy | Reveal Email/Phone |
Merus N.V. Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Merus N.V.?
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
keywords:N/A
N/A
Total Funding
292
Number of Employees
$45.3M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Merus N.V. News
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,...
MRUS received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Merus NV also achieved a score of 87 in...
He is currently the Executive Vice President, Chief Business Officer and Head of US at Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology...
Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indicationMerus presented early clinical data on MCLA-158 at the AACR-NCI-EORTC Virtual International Confer ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pu ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $67.5M | 292 | 62% | N/A |
#2 | $7.5M | 292 | 32% | N/A |
#3 | $4.1M | 293 | 1% | N/A |
#4 | N/A | 296 | 44% | N/A |
#5 | $59.2M | 299 | N/A | N/A |